Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice.
The organoselenium compound diphenyl diselenide (PhSe)(2) has shown interesting antioxidant and neuroprotective activities. On the other hand, this compound has also presented some toxic effects. m-Trifluoromethyl-diphenyl diselenide (m-CF(3)-C(6)H(4)Se)(2), a structural analog of (PhSe)(2), has proven to be antipsychotic and antioxidant in mice. The present study was designed to investigate the anxiolytic-like effect of (m-CF(3)-C(6)H(4)Se)(2) in female mice, employing light/dark box and elevated plus-maze (EPM) tests. The involvement of 5-hydroxytryptamine (5-HT) receptors and monoamine oxidase (MAO) activity in the anxiolytic-like effect was also evaluated. (m-CF(3)-C(6)H(4)Se)(2) (0.1, 10 and 100 mg/kg, p.o.) did not affect locomotor activity as evaluated in the open-field test (OFT). (m-CF(3)-C(6)H(4)Se)(2) at the dose of 100 mg/kg produced an anxiolytic-like action, both in light-dark box and the EPM tests. To evaluate the role of 5-HT receptors in the anxiolytic-like effect of (m-CF(3)-C(6)H(4)Se)(2), a selective 5-HT(1A) receptor antagonist, WAY100635 (0.1 mg/kg, s.c.), a non-selective 5-HT(2A/2C) receptor antagonist, ritanserin (2 mg/kg, i.p.) and a selective 5-HT(3) receptor antagonist, ondansetron (0.1 mg/kg, i.p.) were used. All the antagonists used were able to abolish the anxiolytic-like effect of (m-CF(3)-C(6)H(4)Se)(2). (m-CF(3)-C(6)H(4)Se)(2), at the dose of 100 mg/kg, inhibited the MAO-A activity in mice brain. Taken together these data demonstrated that the anxiolytic-like effect caused by (m-CF(3)-C(6)H(4)Se)(2) seems to be mediated by the involvement of the serotonergic system.
Brüning
César Augusto
CA
Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.
Prigol
Marina
M
Roehrs
Juliano A
JA
Nogueira
Cristina Wayne
CW
Zeni
Gilson
G
D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001007:Anxiety / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D008029:Lighting; D008124:Locomotion / Q000187:drug effects; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D009483:Neuropsychological Tests; D017294:Ondansetron / Q000494:pharmacology; D017646:Organosilicon Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011897:Random Allocation; D011985:Receptors, Serotonin / Q000378:metabolism*; D016713:Ritanserin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology
D014151:Anti-Anxiety Agents; D017646:Organosilicon Compounds; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C546861:m-trifluoromethyl-diphenyl diselenide; D016713:Ritanserin; D017294:Ondansetron; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D008995:Monoamine Oxidase